News

A Critically Relevant One Health/PUBLIC HEALTH approach – revisited…      

New vaccines needed for pathogens infecting animals and humans: One Health - Dr. Thomas P. Monath

Note: Thomas P. Monath, MD http://paxvax.com/about/executive-team/thomas-p-monath-md; http://paxvax.com/sites/default/files/pdf/vaccinenation-2014-most-influential-people-in-vaccines.pdf, an eminent physician virologist/vaccine developer, is also a co-founder of the One Health Initiative Autonomous pro bono team (OHI) and the One Health Initiative website.

 

Published on May 1, 2013

World Vaccine Congress & Expo 2013

Dr Thomas P. Monath, Adjunct Professor at Harvard School of Public Health gives his presentation on 'New vaccines needed for pathogens infecting animals and humans: One Health'.

The World Vaccine Congress & Expo is now in its 13th year and is the biggest and most comprehensive event for the industry. Covering everything from the latest R&D to manufacturing to the corporate development strategies you'll be sure to find answers to all your questions.”

SEE: https://www.youtube.com/watch?v=ZaADs7b2svc [This is instructive and sets the stage for understanding]

Following this talk, in October 2013 the OHI posted more details about this issue:

Vaccines against diseases transmitted from animals to humans: A one health paradigm

“This review focuses on the immunization of animals as a means of preventing human diseases (zoonoses). …”

In simple terms, the idea is to develop vaccines that protect domestic animals and wildlife thereby establishing effective barriers against human infections.  Developing animal vaccines are less expensive and are less strictly regulated than are those for humans.  Hopefully a common sense One Health approach can go forward. http://www.onehealthinitiative.com/publications/Thomas%20P.%20Monath,%20MD%20Sept%202013%20One%20Health%20Vaccine%20Article.pdf  

Originally Posted One Health Initiative NEWS page October 9, 2013 - http://www.onehealthinitiative.com/news.php?query=+A+potential+large+scale+%93One+Health+in+Action%94+...+another+dynamic+case+for+implementing+One+Health%21+ 

*Vaccines against diseases transmitted from animals to humans: A one health paradigm

 

Subsequently a supportive scientific publication December 31, 2014 was Posted:

http://www.onehealthinitiative.com/publications.php?query=Important+One+Health+approach+for+human+protection+via+expanded+animal+vaccination+Plant-based+solutions+for+veterinary+immunotherapeutics+and+prophylactics%2Fimmunization

 

Plant-based solutions for veterinary immunotherapeutics and prophylactics: Veterinary Research 2014, 45:117  doi:10.1186/s13567-014-0117-4 http://www.veterinaryresearch.org/content/45/1/117

 “…So, it is viewed as inevitable by the One Health Initiative that humans need to reduce the use of antibiotics and turn to alternative, improved means to control disease: vaccination and prophylactics. …”

Abstract

“An alarming increase in emergence of antibiotic resistance among pathogens worldwide has become a serious threat to our ability to treat infectious diseases according to the World Health Organization. Extensive use of antibiotics by livestock producers promotes the spread of new resistant strains, some of zoonotic concern, which increases food-borne illness in humans and causes significant economic burden on healthcare systems. Furthermore, consumer preferences for meat/poultry/fish produced without the use of antibiotics shape today’s market demand. So, it is viewed as inevitable by the One Health Initiative that humans need to reduce the use of antibiotics and turn to alternative, improved means to control disease: vaccination and prophylactics.  Besides the intense research focused on novel therapeutic molecules, both these strategies rely heavily on the availability of cost-effective, efficient and scalable production platforms which will allow large-volume manufacturing for vaccines, antibodies and other biopharmaceuticals. Within this context, plant-based platforms for production of recombinant therapeutic proteins offer significant advantages over conventional expression systems, including lack of animal pathogens, low production costs, fast turnaround and response times and rapid, nearly-unlimited scalability. Also, because dried leaves and seeds can be stored at room temperature for lengthy periods without loss of recombinant proteins, plant expression systems have the potential to offer lucrative benefits from the development of edible vaccines and prophylactics, as these would not require cold storage and transportation, and could be administered in mass volumes with minimal processing. Several biotechnology companies currently have developed and adopted plant-based platforms for commercial production of recombinant protein therapeutics. In this manuscript, we outline the challenges in the process of livestock immunization as well as the current plant biotechnology developments aimed to address these challenges.”